WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Inc Stock

$1,100.05+19.78 (+1.83%)
Updated Jul 12, 2024
REGN Price
$1,100.05
Fair Value Price
$2,463.62
Market Cap
$121.21B
52 Week Low
$715.54
52 Week High
$1,106.16
P/E
30.46x
P/B
4.49x
P/S
7.92x
PEG
4.23x
Dividend Yield
N/A
Revenue
$13.10B
Earnings
$3.86B
Gross Margin
86.3%
Operating Margin
31.4%
Profit Margin
29.4%
Debt to Equity
0.27
Operating Cash Flow
$5B
Beta
0.58
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

REGN Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how REGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

REGN ($1,100.05) is undervalued by 55.35% relative to our estimate of its Fair Value price of $2,463.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
REGN ($1,100.05) is significantly undervalued by 55.35% relative to our estimate of its Fair Value price of $2,463.62 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
REGN ($1,100.05) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more REGN due diligence checks available for Premium users.

Be the first to know about important REGN news, forecast changes, insider trades & much more!

REGN News

Valuation

REGN fair value

Fair Value of REGN stock based on Discounted Cash Flow (DCF)
Price
$1,100.05
Fair Value
$2,463.62
Undervalued by
55.35%
REGN ($1,100.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
REGN ($1,100.05) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
REGN ($1,100.05) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

REGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
30.46x
Industry
-12.81x
Market
32.2x
REGN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
REGN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

REGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.49x
Industry
6.45x
REGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

REGN price to earnings growth (PEG)

For valuing profitable companies with growth potential
REGN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

REGN's financial health

Profit margin

Revenue
$3.1B
Net Income
$722.0M
Profit Margin
23%
REGN's Earnings (EBIT) of $4.11B... subscribe to Premium to read more.
Interest Coverage Financials
REGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$34.4B
Liabilities
$7.4B
Debt to equity
0.27
REGN's short-term assets ($18.87B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REGN's short-term assets ($18.87B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
REGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$1.5B
Investing
-$1.7B
Financing
$47.1M
REGN's operating cash flow ($4.74B)... subscribe to Premium to read more.
Debt Coverage Financials

REGN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
REGN$121.21B+1.83%30.46x4.49x
VRTX$126.12B-0.69%31.37x6.80x
MRNA$46.55B-1.11%-7.76x3.63x
ALNY$32.95B-0.20%-98.68x-150.28x
ARGX$27.61B+1.02%-83.16x6.20x

Regeneron Pharmaceuticals Stock FAQ

What is Regeneron Pharmaceuticals's quote symbol?

(NASDAQ: REGN) Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol REGN. Regeneron Pharmaceuticals stock quotes can also be displayed as NASDAQ: REGN.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

What is the 52 week high and low for Regeneron Pharmaceuticals (NASDAQ: REGN)?

(NASDAQ: REGN) Regeneron Pharmaceuticals's 52-week high was $1,106.16, and its 52-week low was $715.54. It is currently -0.55% from its 52-week high and 53.74% from its 52-week low.

How much is Regeneron Pharmaceuticals stock worth today?

(NASDAQ: REGN) Regeneron Pharmaceuticals currently has 110,185,503 outstanding shares. With Regeneron Pharmaceuticals stock trading at $1,100.05 per share, the total value of Regeneron Pharmaceuticals stock (market capitalization) is $121.21B.

Regeneron Pharmaceuticals stock was originally listed at a price of $8.56 in Dec 31, 1997. If you had invested in Regeneron Pharmaceuticals stock at $8.56, your return over the last 26 years would have been 12,746.55%, for an annualized return of 20.53% (not including any dividends or dividend reinvestments).

How much is Regeneron Pharmaceuticals's stock price per share?

(NASDAQ: REGN) Regeneron Pharmaceuticals stock price per share is $1,100.05 today (as of Jul 12, 2024).

What is Regeneron Pharmaceuticals's Market Cap?

(NASDAQ: REGN) Regeneron Pharmaceuticals's market cap is $121.21B, as of Jul 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Regeneron Pharmaceuticals's market cap is calculated by multiplying REGN's current stock price of $1,100.05 by REGN's total outstanding shares of 110,185,503.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.